Entrada Therapeutics Gestione
Criteri Gestione verificati 3/4
Entrada Therapeutics Il CEO è Dipal Doshi, nominato in Aug2017, e ha un mandato di 8.83 anni. la retribuzione annua totale è $ 3.84M, composta da 16.5% di stipendio e 83.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.57% delle azioni della società, per un valore di $ 1.31M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 5.1 anni.
Informazioni chiave
Dipal Doshi
Amministratore delegato
US$3.8m
Compenso totale
| Percentuale dello stipendio del CEO | 16.55% |
| Mandato del CEO | 8.8yrs |
| Proprietà del CEO | 0.6% |
| Durata media del management | 4.8yrs |
| Durata media del Consiglio di amministrazione | 5.1yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, including neuromuscular and ocular conditions. What are the underlying business or industry changes driving this perspective?
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Catalysts About Entrada Therapeutics Entrada Therapeutics is a clinical stage biopharma company developing proprietary genetic medicines for high unmet need diseases, with a focus on neuromuscular and ocular disorders. What are the underlying business or industry changes driving this perspective?Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Fly 26% But Investors Aren't Buying For Growth
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have continued their recent momentum with a 26% gain in the last...Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts
Summary Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy pipeline, with multiple early-stage clinical programs converging on key data readouts in 2026. Despite widening losses, TRDA maintains a strong cash position of $326.8 million, sufficient to fund operations through 3Q27 and support ongoing R&D. The stock trades at a deep valuation discount due to its large cash balance, but faces amplified risk from clustered 2026 clinical catalysts. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 32% But Its Business Still Trails The Industry
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a really impressive month, gaining 32% after a shaky period...Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its latest second-quarter report and things are not looking...Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop
To the annoyance of some shareholders, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares are down a considerable 27% in...Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just kicked off its latest yearly results with some very...Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside
Summary Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 million in reserves and strategic partnerships extend Entrada's runway into 2027, reducing near-term financing risks. ENTR-601-44, targeting Duchenne muscular dystrophy, is entering critical trials, with potential to validate the platform and drive significant market share. Despite scientific and execution risks, successful trials could elevate Entrada's valuation and establish it as a leader in oligonucleotide-based therapies. Read the full article on Seeking AlphaThe Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26%
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shares have had a horrible month, losing 26% after a relatively good period...There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Entrada Therapeutics, Inc.'s ( NASDAQ:TRDA ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a strong...Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Celebrations may be in order for Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders, with the analysts delivering...Entrada Therapeutics: A Complicated Tale
Summary Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficiency, potentially revolutionizing treatment across various diseases. Despite ongoing FDA issues, analysts remain optimistic about Entrada's prospects, with a well-padded balance sheet and potential for future collaborations. An analysis around Entrada Therapeutics stock follows in the paragraphs below. Read the full article on Seeking AlphaEntrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
The Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) share price has done very well over the last month, posting an excellent...These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
One thing we could say about the analysts on Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) - they aren't optimistic...This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Shareholders in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) may be thrilled to learn that the analysts have just...Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) shareholders will have a reason to smile today, with the analysts making...Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
Investors in Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) had a good week, as its shares rose 3.1% to close at US$12.50...Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Entrada Therapeutics press release (NASDAQ:TRDA): Q2 GAAP EPS of -$0.74 misses by $0.02. Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021.We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$166m |
| Dec 31 2025 | US$4m | US$635k | -US$144m |
| Sep 30 2025 | n/a | n/a | -US$103m |
| Jun 30 2025 | n/a | n/a | -US$73m |
| Mar 31 2025 | n/a | n/a | US$25m |
| Dec 31 2024 | US$4m | US$610k | US$66m |
| Sep 30 2024 | n/a | n/a | US$55m |
| Jun 30 2024 | n/a | n/a | US$104m |
| Mar 31 2024 | n/a | n/a | US$23m |
| Dec 31 2023 | US$4m | US$585k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$3m | US$565k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$78m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$6m | US$425k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$41m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$906k | US$385k | -US$27m |
Compensazione vs Mercato: La retribuzione totale di Dipal ($USD 3.84M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.66M ).
Compensazione vs guadagni: La retribuzione di Dipal è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Dipal Doshi (50 yo)
Mr. Dipal Doshi is Independent Director of Azenta, Inc. from January 30, 2025. Mr. Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024.Mr. Do...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$3.84m | 0.57% $ 1.3m | |
| President & COO | 6.6yrs | US$2.22m | 0.55% $ 1.3m | |
| President of Research & Development | 2.4yrs | US$2.25m | 0.22% $ 514.5k | |
| CFO & Treasurer | 5.6yrs | Nessun dato | 0.042% $ 96.4k | |
| General Counsel | 6.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of People | 4.8yrs | Nessun dato | Nessun dato | |
| Chief Corporate Affairs Officer | 3.9yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Regulatory Affairs | 2.4yrs | Nessun dato | Nessun dato | |
| Head of Information Technology | 1.4yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di TRDA è considerato esperto (durata media dell'incarico 4.8 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 8.8yrs | US$3.84m | 0.57% $ 1.3m | |
| Director | 5.5yrs | US$144.39k | 0.36% $ 823.8k | |
| Industry Leader & Independent Director | 5.1yrs | US$167.43k | 0% $ 0 | |
| Independent Chairman of the Board | 9.7yrs | US$202.60k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$150.68k | 0.014% $ 31.9k | |
| Independent Director | 1yr | US$230.93k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$157.55k | 0% $ 0 |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TRDA sono considerati esperti (durata media dell'incarico 5.1 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/07 13:37 |
| Prezzo dell'azione a fine giornata | 2026/06/05 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Entrada Therapeutics, Inc. è coperta da 10 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ioannis Souroutzidis | Cantor Fitzgerald & Co. |
| Paul Choi | Goldman Sachs |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |